Direct-to-Consumer Program for Diabetes, Migraine, Weight-Loss Drugs Launched by Lilly

In a move that sidesteps pharmacy benefit managers, Eli Lilly has launched a direct-to-consumer marketing program that will provide several of the company’s medicines for obesity, migraine, and diabetes at steeply discounted prices, and without the need for a face-to-face doctor visit.

LillyDirect will allow patients to order 14 medications for home delivery. Twelve of these are various types of insulin, all which are capped at $35 per month. The program also includes the weight loss drug Zepbound (tirzepatide) and one migraine medication, Emgality (galcenezumab).

The move comes just as the company launches a public service campaign against using the GLP-1 inhibitor and other Lilly weight-loss drugs simply for cosmetic purposes.

To read the whole story, click here to subscribe.

Related Topics